Having trouble accessing articles? Reset your cache.

Sept. 13 Clinical Quick Takes: Amgen, Atara, MS biomarkers and switching in psoriasis

Clinical holds on two Amgen trials for cardiac safety signal
Amgen (NASDAQ:AMGN) said FDA placed a clinical hold on a Phase I trial of MCL1 inhibitor AMG 397 “to evaluate a safety signal for cardiac toxicity.” Amgen voluntarily halted

Read the full 392 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE